- 1 Title: Feasibility of SARS-CoV-2 virus detection from consumer-grade cotton swabs
- 2 **Running Title:** Alternative swabs for COVID-19 screening
- 3 Keywords: COVID-19, SARS-CoV-2, RT-qPCR, swab, global health
- 4
- 5 Jeremiah J. Minich¹, Farhana Ali², Clarisse Marotz³, Pedro Belda-Ferre³, Leslie Chiang⁴, Justin P.
- 6 Shaffer³, Carolina S. Carpenter⁵, Daniel McDonald³, Jack Gilbert^{3,5,6}, Sarah M. Allard³, Rob Knight^{3,5,7,8},
- 7 Daniel A. Sweeney⁹, Austin D. Swafford^{5*}
- Marine Biology Research Division, Scripps Institution of Oceanography, University of California San
 Diego, La Jolla, CA, USA.
- Division of Gastroenterology, Department of Pediatrics, University of California San Diego, La Jolla,
 CA, USA.
- Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA,
 USA.
- Division of Infectious Diseases, Department of Pediatrics, University of California San Diego, La
 Jolla, CA, USA.
- 16 5. Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.
- 17 6. Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA.
- 18 7. Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA,19 USA.
- 8. Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
- 21 9. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine,
- 22 University of California, San Diego, La Jolla, CA, USA.
- 23 *Corresponding author: adswafford@ucsd.edu
- 24
- 25 Abstract
- 26 To control the growing COVID-19 pandemic, increased testing and containment is essential, yet clinical-
- 27 grade sampling supplies are expensive and rapidly being depleted. We demonstrate the feasibility of using
- 28 alternative consumer-grade swabs stored in 95% ethanol rather than viral transport media to detect SARS-
- 29 CoV-2 from ten hospitalized persons and hospital rooms.

30

31 Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the causative agent of coronavirus disease 19 (COVID-19) has spread to 185 countries resulting in 278,892 deaths and 4,006,257 total confirmed cases as of May 11, 2020 [1-2]. Large-scale testing remains key for controlling viral spread, but sample collection supplies including swabs, viral transport media (VTM) and personal protective equipment (PPE) are being depleted in developed nations like the United States, and are in even shorter supply in low- and middleincome countries [3]. Validation of alternatives strategies such as self-administered testing using consumergrade materials is urgently needed.

39

40 Concerns about consumer-grade materials include the presence of contaminant RNases and/or PCR 41 inhibitors which would promote false negatives during evaluation for the presence of SARS-CoV-2 RNA 42 by reverse transcription and quantitative polymerase chain reaction (RT-qPCR) as noted in the U.S. Centers 43 for Disease Control (CDC) guidance for testing [4]. Similarly, the CDC-recommended VTM requires 44 specialized ingredients and contains antimicrobials likely to interfere with downstream assessment of the 45 microbial context of SARS-CoV-2 that may enable new insights into viral susceptibility and resistance [5]. 46 VTM also maintains viral viability and therefore requires processing in a facility with more stringent 47 biosafety practices compared to inactivating collection methods. Using inactivating sample collection 48 solutions could increase the number of testing laboratories and ameliorate the risks associated with sample 49 transport and processing. Here we demonstrate the feasibility of detecting SARS-CoV-2 RNA from patient 50 and built-environment samples using viral-inactivating storage solutions and alternative medical-grade and 51 consumer-grade swabs.

52

53 Methods

54 *Swab feasibility testing*

55 Six swab types were compared and processed following the standard SARS-CoV-2 protocol provided by
56 the CDC [6] (Supplementary Methods). These swab types are: sterile polyester-head, plastic-shaft ('PE'),

sterile foam-head, plastic-shaft ('BDF'), non-sterile cotton-head, plastic-shaft ('TMI'), non-sterile cottonhead plastic-shaft consumer-grade ('CGp'), non-sterile cotton-head wooden-shaft consumer-grade
('CGw'), and non-sterile cotton-head, wooden-shaft ('Pu'). Suppliers and part numbers are provided in
Supplementary Methods.

61

62 Patient and hospital environmental sampling

63 This study was performed with approval of the UC San Diego Institutional Review Board under protocols 64 #150275 and #200613. All study participants were diagnosed and hospitalized with COVID-19, and both 65 nasal samples and hospital surfaces were collected using three unmoistened swab types (PE, TMI, CGp) 66 immediately placed in a collection tube containing 95% EtOH and stored on dry ice. Collection details and 67 sample processing are provided in the Supplementary Methods.

68

69 Results:

70 We compared the efficiency of extracting and processing RNA from 200 µL of VTM eluent surrounding 71 polyester-tipped plastic-shafted nasopharyngeal (NP) swabs (CDC protocol) to more accessible nares 72 samples collected using PE swabs stored in viral-inactivating alcohol. RNA extraction efficiency was 73 significantly reduced from samples stored in 95% EtOH when extracted from the eluent (n=22), but similar 74 when extracted from the swab head itself (n=18) compared to the CDC protocol (n=39) (Figure 1a). 75 Extracting from the swab head also provided significantly higher SARS-CoV-2 viral load compared to the 76 EtOH eluent of the same patient samples (n=7) (Figure 1b, p=0.032). We separately compared the use of 77 95% EtOH vs 91% isopropanol as the storage media with human RNA and found no impact on extraction 78 efficiency (32.1% and 35.3% recovery respectively) (ANOVA, P>0.05) (Figure 1c). However, in the 79 presence of abundant RNase, 95% EtOH protected both human RNA and SARS-CoV-2 RNA better than 80 91% isopropanol (Figure 1d).

82 We next tested RNA recovery from a range of medical- and consumer-grade swabs (Supplementary 83 Methods). The yield was highest from swab heads compared to eluent regardless of the swab type and 84 whether stored in 95% EtOH (P<0.0001, U=37, Mann-Whitney) or 91% isopropanol (P<0.0001, U=28, 85 Mann-Whitney) (Figure 1e-f). The storage solution did not impact RNA quality (Supplemental Figure 1b, 86 Mann-Whitney, P>0.05), though swab type had a minor impact (Supplemental Figure 1c, Kruskal-Wallis 87 P=0.0325, KW=12.17) [6]. RNA recovery ratio of swab-to-eluent and total yield varied among swab type 88 (P<0.0001, KW=28.37, Kruskal-Wallis for eluent, and P<0.0001, KW=15.43, Kruskal-Wallis for swab-89 heads) (Supplemental Figure 2). CGp swabs had the highest recovery from the swab head, while TMI swabs 90 had the highest overall recovery of RNA from both eluent and direct swab extractions (Supplemental Figure 91 2). Swab type did not impact the ability to detect a linear decrease of positive control human and SARS-92 CoV-2 RNA when extracting directly from either CDC-recommended PE swabs or CGp swabs 93 (Supplemental Figure 3).

94

95 As a clinical proof-of-concept, we collected samples from ten participants admitted to the hospital for 96 COVID-19 using TMI and/or CGp swabs alongside the recommended PE swabs, and performed RT-qPCR 97 per CDC guidelines. All three swab types successfully detected positive control SARS-CoV-2 RNA except 98 for one false negative CGp, and no false positives (Supplemental Figure 4). For this comparison, samples 99 inconclusive solely for the SARS-CoV-2 N2 amplicon (I-N2 in Figure 1g) were considered positive for the 100 presence of SARS-CoV-2 RNA based on observed and reported concerns with this primer set [7]. PE swabs 101 were 100% concordant with NP results when extracting from the swab head compared to 67% concordance 102 for eluent from the same samples. TMI swabs were 85% and 57% concordant while CGp were 70% and 103 56% concordant for swab head and eluent respectively (Figure 1g). To evaluate contamination of SARS-104 CoV-2 RNA on environmental surfaces, we collected and compared swabs from the inside floor and bedrail 105 of the same participants' rooms using the same swab types [8]. Only 3/10 bedrails had detectable SARS-106 CoV-2 with any swab type, while floor samples tested positive for SARS-CoV-2 RNA for at least one swab

type in 9/10 rooms (Figure 1g). Overall, the concordance between PE swabs was ~84% both for CGp
(25/30) and TMI (22/26) across participant and environmental samples (Figure 1d).

109

110 **Discussion:**

111 We provide evidence that nasal samples collected using more widely-available consumer-grade cotton-112 tipped swabs can be stored in viral-inactivating alcohol without compromising the ability to detect SARS-113 CoV-2. The sensitivity for detection of SARS-CoV-2 RNA was comparable between the hospital NP swabs 114 (CDC protocol) and both TMI and CGp nasal swabs when extracting from the swab head. Negative NP 115 results for previously positive participants may be due to viral clearance, the timing of sampling during the 116 course of infection or inconsistencies among the standard NP swabs. Of note, wooden-shafted swabs 117 performed poorly only when extracting from the eluent, suggesting that RNA adsorption onto the shaft 118 rather than RT-qPCR inhibitors may be the source of interference with current eluent-based testing 119 methods.

120 Cotton-tipped swabs and alcohol-based solutions are compatible with standard microbiome and 121 metabolome analyses prohibited by VTM, and could enable more widespread assessment for SARS-CoV-122 2 RNA in human and environmental samples. SARS-CoV-2 was only detected on 30% of participants' 123 bedrails, which may have been due to routine cleaning measures and/or minimal interaction with the 124 surfaces from heavily-sedated or intubated patients. This may be present a challenge for monitoring shared 125 surfaces between the healthcare worker and patients. In contrast, the detection of SARS-CoV-2 RNA from 126 the floor samples demonstrates a potentially important reservoir for viral exposure, as shoe covers are note 127 currently recommended by the CDC. However, additional testing is needed to determine whether viable 128 virus remains on these surfaces.

In summary, our results suggest detection of SARS-CoV-2 RNA could be performed using less expensive,
consumer-grade materials. We add to the emerging body of literature supporting nasal sampling as opposed
to NP sampling [10–14]. It is conceivable that patients could collect samples at home, thus reducing risk

132	and saving the use of PPE for healthcare workers. Further confirmatory studies using consumer-grade swabs
133	would greatly support COVID-19 screening worldwide, particularly in resource-limited settings.
134	
135	Funding:
136	This work was supported by the UC San Diego Center for Microbiome Innovation (CMI). JJM is supported
137	by the National Science Foundation Center for Aerosol Impacts on Chemistry of the Environment
138	#1801971. CM is supported by NIDCR NRSA F31 Fellowship 1F31DE028478-01. PBF is partially funded
139	through trainee support from Sanitarium Health and Wellbeing in partnership with the CMI. DM is partially
140	funded by support from Danone Nutricia Research in partnership with the CMI.

141

142 Acknowledgements:

143 We thank research participants who donated samples, the health care professionals who assisted in the 144 collection of samples, and Alison Vrbanac, Louis-Felix Nothias-Scaglia, and Shi Huang for assistance in 145 transportation and Dominic Nguyen for sampling kit preparation. This research benefited tremendously 146 from lessons learned and techniques developed in the Sloan Microbiology of the Built Environment (MoBE 147 program). We thank Stanley T. Motley for early discussion on nucleic acid stability, Sandrine Miller-148 Montgomery for guidance in RT-qPCR analyses. We thank Thomas F. Rogers and Nathan Beutler for 149 providing the SARS-CoV-2 viral RNA used as a control in this study and David Pride for supplying samples 150 from NP swabs in VTM for our comparisons.

151 The authors have no conflict of interest related to the work described in this manuscript.

152

153

154	4 I	References:

155 1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2.

- 156 Nat Med **2020**; 26:450–452.
- 157 2. Coronavirus disease 2019 (COVID-19) Situation Report 112. WHO, 2020. Available at:
- 158 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200511-covid-19-sitrep-
- 159 112.pdf?sfvrsn=813f2669_2.
- 160 3. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. The Lancet.
- 161 2020; Available at: http://dx.doi.org/10.1016/s0140-6736(20)30798-4.
- 162 4. Oropharyngeal 1., Swabs N. Collection of Upper Respiratory Tract Specimens. Available at:

163 https://www.cdc.gov/urdo/downloads/SpecCollectionGuidelines.pdf.

- 164 5. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention SOP#:
- 165 DSR-052-02- PREPARATION OF VIRAL TRANSPORT MEDIUM. 2020. Available at:
- https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf. Accessed 24
 April 2020.
- 168 6. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity
 169 values to RNA measurements. BMC Mol Biol 2006; 7:3.
- 170 7. Marx V. Coronavirus jolts labs to warp speed. Nat Methods 2020; 17:465–468.
- 171 8. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as
 172 Compared with SARS-CoV-1. N Engl J Med 2020; 382:1564–1567.
- 173 9. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples.
- 174Lancet Infect Dis 2020; 20:411–412.
- 175 10. Xie C, Lu J, Wu D, et al. False negative rate of COVID-19 is eliminated by using nasal swab test.
- 176 Travel Med Infect Dis **2020**; :101668.

177	11.	Yu F. Yan L.	Wang N. et al. (Duantitative Detection and '	Viral Load Analy	vsis of SARS-CoV-2 in
-----	-----	--------------	------------------	-------------------------------------	------------------	-----------------------

- 178 Infected Patients. Clin Infect Dis 2020; Available at: http://dx.doi.org/10.1093/cid/ciaa345.
- 179 12. Petruzzi G, De Virgilio A, Pichi B, et al. COVID -19: Nasal and oropharyngeal swab. Head & Neck.
- 180 2020; Available at: http://dx.doi.org/10.1002/hed.26212.
- 181 13. Péré H, Podglajen I, Wack M, et al. Nasal swab sampling for SARS-CoV-2: A convenient
- alternative in time of nasopharyngeal swab shortage. Journal of Clinical Microbiology. 2020;
- 183 Available at: http://dx.doi.org/10.1128/jcm.00721-20.
- 184 14. Tu Y-P, Jennings R, Hart B, et al. Patient-collected tongue, nasal, and mid-turbinate swabs for
- 185 SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs.
- 186 Available at: http://dx.doi.org/10.1101/2020.04.01.20050005.
- 187 15. CDC. Coronavirus Disease 2019 (COVID-19). 2020. Available at:
- 188 https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html. Accessed 21 April
 2020.
- 190 16. CDC/DDID/NCIRD/ Division of Viral Diseases. CDC 2019-Novel Coronavirus (2019-nCoV) Real-
- 191 Time RT-PCR Diagnostic Panel. **2020**; Available at: https://www.fda.gov/media/134922/download.

193 Figure Legends

Figure 1. Validation of alternative swabs and storage buffer (95% EtOH and 91% isopropanol) in RNA recovery and detection of COVID-19.

196 a) Human RNAse P gene (Rp) RNA extraction control comparison across sample types. Clinical gold-197 standard polyester-tipped plastic-shaft NP swabs stored in VTM and extracted from 200 µL of eluent 198 (left, n=39) have significantly lower higher copy numbers compared to 200 µL EtOH eluent from PE 199 nares swabs (middle, n=22), but not when extracted from the EtOH-preserved swab head (right, n=18). 200 One-way ANOVA with Tukey's multiple comparison VTM eluent vs EtOH eluent p=<0.001, EtOH 201 eluent vs EtOH swab p<0.001, VTM vs EtOH swab p = 0.266. b) Extrapolated viral RNA copy number 202 from nares samples collected with BD polyester swabs in the hospital stored in 95% EtOH and extracted 203 from either the eluent or swab from the same sample(one-tailed paired Student's T-test p=0.032). c) 204 Proportion of recovered RNA across three storage buffers: None, 95% EtOH, and 91% isopropanol (ns, 205 ANOVA p>0.05). d) Evaluation of RNaseA inhibition by 95% EtOH (grey) and 91% isopropanol (blue) 206 (multiple t-test) using either the human Rp or SARS-CoV-2 N1 primer set. e) Comparison human RNA 207 recovery across six swab types (PE=polyester 'commercial', BDF=BD foam 'commercial', TMI=BD 208 TMI 'commercial', CGp=plastic 'consumer grade', Pu=Puritan 'commercial', CGw=wood 'consumer 209 grade'), extracted from 200uL eluent (blank bar) or the swab head. Recovery for each swab type is 210 normalized to the CDC recommended method (eluent from PE swab). A '2' would indicate there was 2x 211 more RNA recovered whereas a 0.5 would indicate a 50% reduction in RNA recovery. f) Total RNA 212 copies per extraction for all samples which are grouped by sample-type (eluent or swab head) and storage 213 buffer (95% EtOH or 91% isopropanol). Pairwise comparisons performed within sample-type (not 214 significant) and across sample-type controlling for storage buffer (Mann-Whitney, U=test statistic). g) 215 Demonstration of consumer-grade CGp and bulk TMI swab congruence compared to clinical-grade 216 hospital tests using polyester-tipped plastic shafted NP swabs across ten patient rooms. Samples positive 217 (+, dark blue background) or negative (-, orange background) for N1, N2, and Rp by CDC guidelines. 218 Samples positive for N1 and Rp, but negative for N2 are labeled inconclusive for N2 (I-N2, blue) but

- 219 considered positive for comparisons. Samples positive for N2 and Rp, but negative for N1 (I-N1, light
- blue) are inconclusive. Samples not measured for a given patient are labeled as NaN (light grey). (P<0.05

221 =
$$*, P < 0.01 = **, P < 0.001 = ***, P < 0.0001 = ****)$$

- 222
- 223 Figures
- Figure 1. Validation of alternative swabs and storage buffer (95% EtOH and 91% isopropanol) in
- 225 RNA recovery and detection of COVID-19.



226

10

NaN

I-N2

NaN

I-N2

I-NC

I-N2

228 Supplementary Methods

229 VTM versus EtOH sample comparison

- 230 Nasopharyngeal (NP) swabs were collected according to CDC guidelines and stored in viral transport
- 231 media (VTM). For comparison, sterile polyester-head, plastic-shaft ('PE', BBL Culture swab REF-
- 232 220135, Becton, Dickinson and Company) were used to collect nares samples by rotating the dry swab
- 233 head in the nares for approximately 30 seconds from lab members, patients, or healthcare workers, and
- then immediately placed in 95% EtOH. Eluent nucleic acid extractions were performed on 200 µL of the
- swab eluent (either VTM or EtOH) using the Omega Mag-Bind® Viral DNA/RNA 96 Kit (catalog#
- 236 M6246-03), which only uses chemical lysis and does not include a bead beating step. For nucleic acid
- extraction from the swab head, the MagMAX Microbiome Ultra kit (Cat#A42357, Thermo Fisher
- 238 Scientific) was used. For the direct comparison of SARS-CoV-2 extraction efficiency, we extracted EtOH
- eluent and swab separately from the same samples of COVID-19 patients with approval of the UC San
- 240 Diego Institutional Review Board under protocols #150275 and #200613
- 241

242 Patient and hospital environmental sampling

243 All study patients were diagnosed and hospitalized with COVID-19 with approval of the UC San Diego 244 Institutional Review Board under protocols #150275 and #200613. Both nasal samples and hospital 245 surfaces were collected using three unmoistened swab types (PE, TMI, CGp; see Table 1). Nasal samples 246 were collected by inserting the swab into one nostril to the depth of approximately 2-3 cm and rotated for 247 5-10 seconds. Hospital surfaces sampled included the floor inside the patient's room (approximately 1x1 248 square foot area) and the patient's bedrail. All swabs were immediately placed in a collection tube 249 containing 0.5-1 mL 95% ethanol and stored on dry ice and processed for RNA or total nucleic acid 250 extraction (Supplementary Methods).

- 251
- 252 RT-qPCR for VTM and 95% EtOH comparison using polyester-tipped plastic swabs

253	SARS-CoV-2 detection was	performed following a	slightly miniaturized	version of the CDC	protocol.

- Each RT-qPCR reaction contained 4μl RNA template, 100nm forward and reverse primers, 200nm probe,
- 255 3µl TaqPath (catalog# A15299, Thermo), and RNAse free water to a total reaction volume of 10µl. All
- primers and probes were ordered from IDT (catalog# 10006606). RT-qPCR was performed on the Bio-
- rad CFX384 Touch Real-Time PCR Detection System following the CDC thermocycling guidelines.
- 258 Serial dilutions of the Hs_RPP30 Positive Control plasmid (catalog# 10006626, IDT) or 2019-
- 259 nCoV N Positive Control plasmid (catalog# 10006625, IDT) were included to extrapolate human
- 260 RNAse P and SARS-CoV-2 copy numbers, respectively.
- 261
- 262 Alternative swab list
- 263 Six swab types were used: sterile polyester-head, plastic-shaft ('PE', BBL Culture swab REF-220135,
- 264 Becton, Dickinson and Company); sterile foam-head, plastic-shaft ('BDF', Flock PurFlock REF-25-3606-
- 265 U-BT, Becton, Dickinson and Company); non-sterile cotton-head, plastic-shaft in use by The Microsetta
- 266 Initiative ('TMI', SKU#839-PPCS, Puritan Medical Products); non-sterile cotton-head plastic-shaft
- 267 consumer-grade ('CGp' Part #165902, CVS Caremark Corp.); non-sterile cotton-head wooden-shaft
- 268 consumer-grade ('CGw', Part#858948, CVS Caremark Corp.); and non-sterile cotton-head, wooden-shaft
- 269 ('Pu', REF-806-WC, Puritan Medical Products).
- 270
- 271 Controls for RNA extraction efficiency testing

272 Approximately 600 ng of purified, DNA-free human lung RNA (Cat#AM7968, Thermo Fisher Scientific)

273 was pipetted onto each of the six swab types in triplicate and stored in two storage solutions (500 µL 95%

- ethanol (EtOH) and 500 µL 91% isopropanol). Two sets of six, 10-fold serial dilutions of human RNA
- 275 were included as controls. The same quantity of RNA (600 ng) was added to either 95% EtOH (n=6) or
- 276 91% isopropanol (n=6) in the presence of 25 μg RNaseA to determine the resistance offered against
- 277 RNase contaminants. Four negative (swab only) and four positive (swab + 500 ng spiked human RNA + 5

- μL spiked SARS-CoV-2 RNA ~20,000 copies per ul) controls were included, in addition to three, 10-fold
 serial dilutions of this mixture in 95% EtOH.
- 280
- 281 *Extraction and RT-qPCR of hospital swabs and controls*
- All samples were processed according to the manufacturer's protocol using the MagMAX Microbiome
- 283 Ultra kit (Cat#A42357, Thermo Fisher Scientific) and eluted into 70 μL buffer. For RT-qPCR, 5 μL
- sample was processed in duplicate with averaged Ct values, using the standard SARS-CoV-2 protocol
- provided by the CDC (Cat# 2019-nCoVEUA-01[15]). Both the swab head and 200 µL of eluent were
- processed for nasal samples, but only the swab head was processed for floor, bedrail and spiked control
- samples using the same methods.
- 288
- 289 *Statistics and visualizations*
- 290 Visualizations and statistical comparisons performed using PRISM 8.0 and the limit of detection
- 291 determination were consistent with CDC recommendations whereby samples with a Ct value greater than
- 40 are omitted [16].
- 293

294	Supplementary Figures Legends
295	Supplemental S1. Impacts of storage solution or swab type on RNA quality as measured by RNA
296	Tapestation High Sensitivity kit. a) All direct-swab extracted RNA grouped by storage buffer and swab
297	type. b) Samples grouped by storage buffer, no significant difference in RNA integrity number (RIN)
298	values between storage buffers (95% EtOH vs. 91% isopropanol) (Mann-Whitney). c) Swab extracts
299	grouped by swab type only and compared to determine if swab type has an impact on RNA quality
300	(Kruskal-Wallis test).
301	
302	Supplemental Figure S2. Impacts of sample-type (eluent vs. swab head) on RNA recovery by swab
303	used. Comparison human RNA recovery across six swab types (PE=polyester 'commercial', BDF=BD
304	foam 'commercial', TMI=BD TMI 'commercial', CGp=plastic 'consumer grade', Pu=Puritan
305	'commercial', CGw=wood 'consumer grade'), a) extracted from 200 μ L eluent or b) swab head (Group
306	comparison using Kruskal-Wallis)
307	
308	Supplemental Figure 3. Demonstration of impact of swab or storage buffer on human RNA and
309	SARS-CoV-2 detection. a) Positive (swab + SARS-CoV-2 RNA + human RNA, n=4) and negative
310	(swab only, n=4) controls from hospital processing experiment. b) Serial dilution of positive controls in
311	95% EtOH to demonstrate conserved extraction efficiency across biomass. Three swab types:circle-PE,
312	square=CGp, triangle=TMI.
313	
314	Supplemental Figure 4. Hospital built environment and patient screen for SARS-CoV-2.
315	Demonstration of consumer-grade CGp and bulk TMI swab congruence compared to CDC polyester in a
316	hospital setting across ten patient rooms and three sampling environments (bedrail, floor, and nasal swab)
317	including negative and positive controls. Samples positive (+, dark blue background) or negative (-,
318	orange background) for N1, N2, and Rp by CDC guidelines. Samples positive for N1 and Rp, but
319	negative for N2 are labeled inconclusive for N2 (I-N2, blue) but considered positive for comparisons.

- 320 Samples positive for N2 and Rp, but negative for N1 (I-N1, light blue) are inconclusive. Samples not
- 321 measured for a given patient are labeled as NaN (light grey). All data except controls are identical to
- those in Figure 1g.
- 323
- 324 Supplementary Figures
- 325 Supplemental S1. Impacts of storage solution or swab type on RNA quality as measured by RNA
- 326 Tapestation High Sensitivity kit.



328

329 Supplemental Figure S2. Impacts of sample-type (eluent vs. swab head) on RNA recovery.



331 Supplemental Figure 3. Demonstration of impact of swab or storage buffer on human RNA and







335 Supplemental Figure 4. Hospital built environment and patient screen for SARS-CoV-2.

		Experimental					Hospital (Built Environment)						Hospital (patient)						
	- controls				+ controls		bedrail		floor			nasal (swab)			nasal (Eluent)				
Room	Hospital	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp	PE	TMI	CGp
1	+	-	-	-	+	+	+	-	-	-	+	+	I-N2	+	+	+	I-N2	+	+
2			-		+	+	+	-			+	+	+	I-N1	I-N1	+		+	-
3		-	-	-	+	+	+	-				+	-	NaN	-	-	NaN	-	-
4	+				+	+	+			I-N2		-		NaN			NaN		-
5	+		-		+	+	+	-				I-N1	+	NaN	+	+	NaN		-
6	+		-	-	+	+	I-N2	-			-	I-N1	+	NaN	+	-	NaN	-	-
7	+	-	-	-	I-N2	+	I-N2	-	-	-	I-N2	+	I-N2	I-N2	NaN	I-N2		NaN	-
8	+				I-N2	I-N2	-	I-N2	I-N2	I-N2	I-N2	-	I-N2	+	NaN	+	I-N2	NaN	I-N2
9	-	NaN	-	NaN	NaN	NaN	NaN	-	-	-	I-N2	-	-	-	-	NaN	-	-	NaN
10	+	NaN	NaN	NaN	NaN	NaN	NaN	I-N2	I-N2	I-N2	I-N2	+	I-N2	+	NaN	+	I-N2 (low)	NaN	+

337